Amylin Pharmaceuticals Inc. said on Friday that a high dose of its diabetes drug Symlin, given three times a day by injection, helped obese patients shed weight in a mid-stage clinical trial.
A phase II trial of 204 obese subjects found they lost 3.6 percent of their weight after 16 weeks of treatment, the company said.
The results, to be presented at medical meetings in Athens, Greece and San Diego, also showed that the weight loss was progressive and did not show signs of a plateau, said Dan Bradbury, chief operating officer, at San Diego-based Amylin.
Experiments in rats suggest that minocycline, an antibiotic, could curb a common cause of vision problems in people with diabetes.
Minocycline is a “strong candidate for further consideration as a therapeutic drug in reducing the retinal complications of diabetes,” Dr. J. Kyle Krady and colleagues from the Pennsylvania State University College of Medicine in Hershey write in the medical journal Diabetes.